Floatz logo

Arbaclofen

Spasticity, Muscle

RVL Pharmaceuticals, Inc.Phase 3Dormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Spasticity, Muscle cohort.

Asset / SponsorPhaseRating
Meditoxin
Medy-Tox
Phase 4BB
Xeomin®
Sisli Hamidiye Etfal Training and Research Hospital
Phase 4BB
ABOBOTULINUMTOXINA
Neurology Center of New England P.C.
Phase 3CCC
Bont A
Kayseri City Hospital
N/AD
AUTOLOGOUS CONDITIONED PLASMA
Ege University
N/AD

Same molecule, other indications

Arbaclofen is also rated in:

SpasticityDormant
BB
Indicative ·
68 / 100
View asset →
multiple sclerosisDormant
BB
Indicative ·
65 / 100
View asset →
SpermDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →